Two covid jobs should still outweigh the risk of dying omicron According to official estimates, up to 84 percent but the booster is twice as good at preventing someone from getting sick.
sage Modeling published over the weekend shattered the notion that the two pfizer The supplements provide 83.7 percent protection against hospitalization and death from highly developed stress.
two-dose course astraZenecaThe vaccine was estimated to reduce the risk of serious disease caused by Omicron by 77.1 percent. However, both the vaccine brands were phased out within three to six months.
At the time, the government’s scientific advisers believe the safety from the two AstraZeneca jabs could be at least 61.3 percent for Pfizer and 67.6 percent for Pfizer.
A booster dose of Pfizer’s vaccine was estimated to increase immunity by more than 93 percent regardless of the one originally given the jab – providing the same level of protection as the two doses against Delta did.
The estimates were presented in modeling on Saturday by the London School of Hygiene and Tropical Medicine (LSHTM) and are based on laboratory studies looking at antibodies.
Scientists have been racing to determine how effective existing vaccines would perform on the Omicron strain since they were first discovered on November 24. There was great concern that the vaccine would be virtually unrecognizable due to more than 30 mutations on its spike protein. The current jabs were designed to target the original virus that emerged in Wuhan. But because the version is so new, experts are still relying on lab experiments that may not reflect how the version would behave in the real world.
Professor Paul Hunter, an expert in infectious diseases at the University of East Anglia, told MailOnline that he expects to protect against serious disease twice as much as lab studies suggest. He said hospital data at Omicron Ground Zero in South Africa suggested that T cells, which are more difficult to measure, were playing a key role in immunity.
However, Dr Simon Clark, a microbiologist at the University of Reading, said the decline in efficacy of the two jabs is still ‘concerning’. He told MailOnline: ‘No one expected Omicron to erase the effectiveness of the vaccine, it was just a drop that was expected – and that in itself could do substantial harm.’
Even at 84 percent protection against serious illness, that leaves 16 percent more vulnerable to being hospitalized or killed by Omicron. This is three times more than Delta.
These vaccine effectiveness estimates were presented in modeling Saturday by the London School of Hygiene and Tropical Medicine (LSHTM) and are based on laboratory studies looking at antibodies rather than real-world data. It refers to ‘vaccine effectiveness’ on symptomatic disease and hospitalization/death from Omicron. The dots represent the number of people out of a group of 100 who are vulnerable to COVID. For example, the study found that the booster provided 93 percent protection against hospitalization and death. In a group of 100 people who have had booster vaccinations, you would expect that seven people would need hospital care.
The UK COVID Alert level was raised from Level 3 to Level 4 after the UK’s Omicron edition reported another 1,239 confirmed cases
The LSHTM paper estimated that two doses of AstraZeneca’s jab provided only 36.1 percent protection against symptomatic omicrons after six months, and Pfizer only 46.7 percent.
Early real-world data from the first 500 omicron cases in the UK suggests that the AstraZenca vaccine offers even less protection against mild disease.
By comparison, the LSHTM model assumed that a booster Pfizer jab reduces the risk of symptomatic infection by 80.3 percent.
The team’s estimate of the vaccine’s effectiveness was based on neutralizing antibody studies that test Omicron against the blood of vaccinated people.
While antibodies are a good indicator of immunity, they are just one part of a more complex immune response to a virus that also includes T and B cells.
Professor Hunter told MailOnline that the paper’s estimates had ‘grounds for optimism’.
He said: ‘We have T cells as well as antibodies, and there is some evidence that T cell immunity is better protected between older forms and omicrons than antibodies.
‘The big issue here is that all their results are conjectures based on neutralizing antibodies and while this is probably accurate for infection and symptomatic disease, it is slightly different when looking at severe disease.
‘So there’s reason to hope that their [the LSHTM’s] The estimates of protection against hospitalization and death may actually be better – even by two doses.
‘There is some world evidence from South Africa that this can happen.’
While hospitalizations are on the rise in South Africa, data shows that patients are coming in with minor illnesses and being discharged early.
In Tshwane in Guateng province, one of the epicenters of the new outbreak, only a quarter of patients admitted for COVID since November had serious illness, compared to 65 percent at the same point in the delta wave. And nationally, South Africa is recording an average of less than 40 Covid deaths per day.
But Dr Clarke cautioned against being complacent about the figures, saying Omicron’s hyper-infectivity in itself could be enough to overwhelm the NHS.
Experts at No10 warn that there could be an astronomical one million omicron infections per day by the new year – about 20 times the current rate.
While scientists are divided over the prospect of Britain actually reaching such a level, Dr Clarke said: ‘We must not overlook the transmissibility element.
“If we are talking about 1 million cases per day, we would expect a 20-fold increase in the number of people who end up in hospital. Even if you take half of that, there are still 10 times more patients in the NHS.’ There are currently 800 Covid patients admitted to UK hospitals daily.
On reports of omicrons being softer than previous variants, Dr Clark cautioned that even if this is the case, the strain could make the strain jabs so weak that it creates a ‘mass sickness’.
‘We may end up with a society and economy that slows down and almost shuts down, not because people are in hospital but because people are sick at home and cannot work.’
If true, the LSHTM paper estimated that two vaccine doses could provide 36 percent protection against symptomatic infection, well below the international vaccine limit.
The World Health Organization (WHO) said that when COVID jabs were first put into development, they must cut the risk by at least 50 percent to be considered for approval.
But Professor Hunter stressed that the UK’s new turbocharged booster program should avoid the wave of hospital admissions with previous peaks by boosting immunity above that threshold, thanks to a combination of natural and vaccine-induced immunity.
He told MailOnline, ‘I believe we have more security than anyone can imagine. In the case of South Africa, they seem to be doing [fine] Even without boosters because they have high levels of natural infection, although we will have to wait a few more weeks before we can be sure.’
The LSHTM model also looked at the worst-case scenario, in which immunity of less than two jaws provided a 45 percent protection against hospital admission and death.
But experts said this was too pessimistic and is unlikely to be true in the real world. In that scenario, a booster dose may provide just 83.7 percent protection against serious disease.
Professor Lawrence Young, a microbiologist at the University of Warwick, said he was ‘cautiously optimistic’ that the boosters would provide even better immunity in the real world and would be enough to circumvent the harsh restrictions.
But because of the two-week lag between getting a booster and developing immunity, he said mild social restrictions were necessary to keep infections down in the meantime.
He told MailOnline: ‘One of the many challenges with the Super-Charge Booster campaign is that it takes about 10-14 days for the booster jab to confer a high level of protective immunity.
‘This emphasizes the importance of other protective measures to prevent further infection and I believe that Plan B is sufficient.’
,